



The Terry Fox Research Institute
L'Institut de recherche Terry Fox

Backgrounder

Prostate cancer is the most commonly diagnosed and third-leading cause of cancer-related death in Canadian men. It is diagnosed through a PSA blood test and this has significantly increased early diagnosis of the disease. While three out of every four cases of prostate cancer will not be lethal, the current standard is to treat all patients aggressively for the disease through surgery, radiation or therapeutics – because currently there are no ways to predict what patients will require treatment and those who won't. Since the treatment itself can compromise quality of life and contribute to morbidity, oncologists and urologists who treat the disease need better decision-making tools to determine the appropriate course of action for each patient. Having new biomarkers to assist doctors in treatment decisions and to observe how well patients with advanced prostate respond to therapy, will help to improve the standard of care and quality of life for these patients.

Study details

- Type: Retrospective and prospective study.
- Investigators at participating sites will contribute samples and serum from their cohorts and will identify predictive and prognostic biomarkers.
- Study duration: Currently underway until March 2016.

Participating Investigators and Institutions by Province

(Note that each co-principal investigator has a complete research team involved in this project)

Quebec	Ontario	British Columbia	Knowledge transfer
<p>CHUM Research Centre (CRCHUM) Central coordination for the CPCBN <i>Principal Investigator:</i> Dr. Fred Saad</p> <p><i>Co-Principal Investigator:</i> Dr. Anne-Marie Mes-Masson</p> <p><i>Co-investigators:</i> Dr. Mathieu Latour Pathology Dr. Louis-Mathieu Stevens Bio-Statistics Dr. Jean-Baptiste Lattouf Uro-Oncology</p> <p><i>Project Manager</i> Dr. Véronique Ouellet</p>	<p>Sunnybrook Health Sciences Centre and University of Toronto <i>Co-Principal Investigator:</i> Dr. Laurence Klotz</p>	<p>Vancouver Prostate Centre, Vancouver Coastal Health & University of British Columbia <i>Co-Principal Investigator:</i> Dr. Martin Gleave</p>	<p>Quebec Dr. Jean-Baptiste Lattouf (CRCHUM) Dr. Alain Maillette (Centre Hospitalier de Trois-Rivières) Dr. Marie-Paule Jammal (Cité-de-la-Santé de Laval)</p> <p>British Columbia Dr. Alan So (VPC) Dr. Tom Pickles (UBC)</p> <p>Manitoba Dr. Darrel Drachenberg (University of Manitoba, Manitoba Prostate Centre)</p> <p>Ontario Dr. Shabbir Alibhai UHN Dr. Antonio Finelli UHN Dr. Margaret Fitch UHN</p> <p>Consultant Dr. Simon Sutcliffe (TFRI)</p>
<p>McGill University, McGill University Health Centre (MUHC), Research Institute of the MUHC <i>Co-Principal Investigators:</i> Dr. Armen Aprikian Dr. Simone Chevalier</p>	<p>UHN-University Health Network, Princess Margaret Hospital and University of Toronto <i>Co-Principal Investigator:</i> Dr. Neil Fleshner Dr. Robert Bristow</p>		
<p>Université Laval, Laval University Cancer Research Centre, CHUQ <i>Co-Principal Investigator:</i> Dr. Louis Lacombe</p>	<p>Kingston General Hospital, Queen's University and NCIC Clinical Trials Group <i>Co-Principal Investigator:</i> Dr. Jeremy Squire</p>		